Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper
Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell products could result in improved outcomes. However, it remains a complex and expensive technology, which poses challenge...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 September 2022
|
| In: |
The lancet. Haematology
Year: 2022, Jahrgang: 9, Heft: 10, Pages: e786-e795 |
| ISSN: | 2352-3026 |
| DOI: | 10.1016/S2352-3026(22)00226-5 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S2352-3026(22)00226-5 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2352302622002265 
|
| Verfasserangaben: | Nico Gagelmann, Anna Sureda, Silvia Montoto, John Murray, Natacha Bolaños, Michelle Kenyon, Meral Beksac, Stefan Schönland, Patrick Hayden, Hans Scheurer, Kate Morgan, Laurent Garderet, Donal P McLornan, Annalisa Ruggeri |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1832790207 | ||
| 003 | DE-627 | ||
| 005 | 20230706235352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230131s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2352-3026(22)00226-5 |2 doi | |
| 035 | |a (DE-627)1832790207 | ||
| 035 | |a (DE-599)KXP1832790207 | ||
| 035 | |a (OCoLC)1389535981 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gagelmann, Nico |e VerfasserIn |0 (DE-588)1203322240 |0 (DE-627)168815017X |4 aut | |
| 245 | 1 | 0 | |a Access to and affordability of CAR T-cell therapy in multiple myeloma |b an EBMT position paper |c Nico Gagelmann, Anna Sureda, Silvia Montoto, John Murray, Natacha Bolaños, Michelle Kenyon, Meral Beksac, Stefan Schönland, Patrick Hayden, Hans Scheurer, Kate Morgan, Laurent Garderet, Donal P McLornan, Annalisa Ruggeri |
| 264 | 1 | |c 26 September 2022 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 31.01.2023 | ||
| 520 | |a Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell products could result in improved outcomes. However, it remains a complex and expensive technology, which poses challenges to health-care systems and society in general, especially in times of crises. This potentially accelerates pre-existing inequalities as access to CAR T-cell therapy varies, both between countries, depending on the level of economic development, and within countries, due to structural disparities in access to quality health care—a parameter strongly correlated with socioeconomic status, ethnicity, and lifestyle. Here, we identify two important issues: affordability and access to CAR T-cell treatment. This consensus statement from clinical investigators, clinicians, nurses, and patients from the European Society for Blood and Marrow Transplantation (EBMT) proposes solutions as part of an innovative collaborative strategy to make CAR T-cell therapy accessible to all patients with multiple myeloma. | ||
| 700 | 1 | |a Sureda, Anna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Montoto, Silvia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Murray, John |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bolaños, Natacha |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kenyon, Michelle |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beksac, Meral |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schönland, Stefan |d 1969- |e VerfasserIn |0 (DE-588)122405226 |0 (DE-627)705896137 |0 (DE-576)293255792 |4 aut | |
| 700 | 1 | |a Hayden, Patrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scheurer, Hans |e VerfasserIn |4 aut | |
| 700 | 1 | |a Morgan, Kate |e VerfasserIn |4 aut | |
| 700 | 1 | |a Garderet, Laurent |e VerfasserIn |4 aut | |
| 700 | 1 | |a McLornan, Donal P |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ruggeri, Annalisa |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Haematology |d London [u.a.] : Elsevier, 2014 |g 9(2022), 10 vom: Okt., Seite e786-e795 |h Online-Ressource |w (DE-627)810540304 |w (DE-600)2802056-X |w (DE-576)420435689 |x 2352-3026 |7 nnas |a Access to and affordability of CAR T-cell therapy in multiple myeloma an EBMT position paper |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g number:10 |g month:10 |g pages:e786-e795 |g extent:10 |a Access to and affordability of CAR T-cell therapy in multiple myeloma an EBMT position paper |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S2352-3026(22)00226-5 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2352302622002265 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230131 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 122405226 |a Schönland, Stefan |m 122405226:Schönland, Stefan |d 910000 |d 910100 |d 50000 |e 910000PS122405226 |e 910100PS122405226 |e 50000PS122405226 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1832790207 |e 4255619875 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Gagelmann","display":"Gagelmann, Nico","given":"Nico","role":"aut"},{"role":"aut","given":"Anna","display":"Sureda, Anna","family":"Sureda"},{"family":"Montoto","display":"Montoto, Silvia","role":"aut","given":"Silvia"},{"role":"aut","given":"John","family":"Murray","display":"Murray, John"},{"family":"Bolaños","display":"Bolaños, Natacha","role":"aut","given":"Natacha"},{"family":"Kenyon","display":"Kenyon, Michelle","given":"Michelle","role":"aut"},{"role":"aut","given":"Meral","display":"Beksac, Meral","family":"Beksac"},{"given":"Stefan","role":"aut","display":"Schönland, Stefan","family":"Schönland"},{"display":"Hayden, Patrick","family":"Hayden","role":"aut","given":"Patrick"},{"display":"Scheurer, Hans","family":"Scheurer","role":"aut","given":"Hans"},{"display":"Morgan, Kate","family":"Morgan","given":"Kate","role":"aut"},{"given":"Laurent","role":"aut","display":"Garderet, Laurent","family":"Garderet"},{"family":"McLornan","display":"McLornan, Donal P","given":"Donal P","role":"aut"},{"display":"Ruggeri, Annalisa","family":"Ruggeri","given":"Annalisa","role":"aut"}],"language":["eng"],"title":[{"title_sort":"Access to and affordability of CAR T-cell therapy in multiple myeloma","subtitle":"an EBMT position paper","title":"Access to and affordability of CAR T-cell therapy in multiple myeloma"}],"origin":[{"dateIssuedDisp":"26 September 2022","dateIssuedKey":"2022"}],"note":["Gesehen am 31.01.2023"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"10 S."}],"name":{"displayForm":["Nico Gagelmann, Anna Sureda, Silvia Montoto, John Murray, Natacha Bolaños, Michelle Kenyon, Meral Beksac, Stefan Schönland, Patrick Hayden, Hans Scheurer, Kate Morgan, Laurent Garderet, Donal P McLornan, Annalisa Ruggeri"]},"relHost":[{"recId":"810540304","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2802056-X"],"issn":["2352-3026"],"eki":["810540304"]},"origin":[{"dateIssuedDisp":"2014-","publisher":"Elsevier","dateIssuedKey":"2014","publisherPlace":"London [u.a.]"}],"note":["Gesehen am 27.11.14"],"pubHistory":["1.2014 -"],"title":[{"title":"The lancet","title_sort":"lancet","partname":"Haematology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Access to and affordability of CAR T-cell therapy in multiple myeloma an EBMT position paperThe lancet. Haematology","language":["eng"],"part":{"volume":"9","extent":"10","text":"9(2022), 10 vom: Okt., Seite e786-e795","issue":"10","pages":"e786-e795","year":"2022"},"titleAlt":[{"title":"The lancet <London> / Haematology"}]}],"recId":"1832790207","id":{"eki":["1832790207"],"doi":["10.1016/S2352-3026(22)00226-5"]}} | ||
| SRT | |a GAGELMANNNACCESSTOAN2620 | ||